Europska unija — odluke Europske komisije — studeni 2026.
Ukinuta odobrenja, povlačenje serija lijekova, pisma zdravstvenim radnicima i novi lijekovi EU — svakodnevno, automatski. Zadnje ažuriranje: 16. 11. 2026. 08:55
Izvori: promjene pratimo na temelju informacija Agencije za lijekove i medicinske proizvode (HALMED) — rješenja o ukidanju odobrenja, obavijesti o povlačenju serija i pisma zdravstvenim radnicima. Odluke o centralizirano odobrenim lijekovima dolaze iz registra Unije Europske komisije (oznaka EU). Nestašice i liste lijekova HZZO-a ovdje (još) nisu uključene.
br. EU/1/26/2074 · FREHEMGO is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital … · Novo Nordisk A/S · denecimig
br. EU/1/24/1849 · odobreno 22. 8. 2024. · mRESVIA is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caus… · MODERNA BIOTECH SPAIN, S.L. · Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation · ATC J07BX05
br. EU/1/21/1617 · odobreno 14. 2. 2022. · Ngenla is indicated for the treatment of children and adolescents from 3 years of age with growth disturbance … · Pfizer Europe MA EEIG · somatrogon · ATC H01AC08
br. EU/1/24/1862 · odobreno 25. 9. 2024. · Plaque psoriasis
Fymskina is indicated for the treatment of moderate to severe plaque psoriasis in adults who… · Formycon AG · ustekinumab · ATC L04AC05
br. EU/1/20/1506 · odobreno 5. 2. 2021. · Kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and abo… · Biosimilar Collaborations Ireland Limited · Insulin aspart · ATC A10AB05
br. EU/1/23/1764 · odobreno 1. 12. 2023. · Zilbrysq is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG… · UCB Pharma S.A. · zilucoplan · ATC L04AJ06
br. EU/1/18/1318 · odobreno 20. 9. 2018. · Slenyto is indicated for:
- treatment of insomnia in children and adolescents aged 2-18 years with Autism Spe… · RAD Neurim Pharmaceuticals EEC SARL · melatonin · ATC N05CH01
br. EU/1/25/1958 · odobreno 17. 7. 2025. · Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal… · Sandoz GmbH · denosumab · ATC M05BX04
br. EU/1/20/1501 · odobreno 31. 3. 2021. · Paediatric patients
Sogroya is indicated for treatment of growth failure in children and adolescents in the… · Novo Nordisk A/S · somapacitan · ATC H01AC07
br. EU/1/20/1480 · odobreno 24. 9. 2020. · Rheumatoid arthritis:
Jyseleca is indicated for the treatment of moderate to severe active rheumatoid arthrit… · Alfasigma S.p.A. · filgotinib · ATC L04AF04
br. EU/1/24/1905 · odobreno 14. 2. 2025. · Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal… · Celltrion Healthcare Hungary Kft. · Denosumab · ATC M05BX04
br. EU/1/20/1439 · odobreno 30. 5. 2020. · Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of ag… · Novartis Europharm Limited · indacaterol / mometasone furoate · ATC R03AK14